Drug Trial Radar · NCT03502785
INO-5401 + INO-9012 in Combination With Atezolizumab in Locally Advanced Unresectable or Metastatic/Recurrent Urothelial Carcinoma
Last checked: Nov 19, 2026Latest source record: Sep 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
35
Actual
Start
Jul 24, 2018
Primary completion
May 9, 2025
Study completion May 9, 2025
Sponsor
- Lead sponsor
- Inovio PharmaceuticalsIndustry
- Sponsor type
- Industry
- First posted
- Apr 19, 2018
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This was a Phase I/IIA, open-label, multi-center trial to evaluate the safety, immunogenicity and preliminary clinical efficacy of INO-5401 + INO-9012 delivered by intramuscular (IM) injection followed by electroporation (EP), in combination with atezolizumab in participants with locally advanced unresectable or metastatic/recurrent Urothelial Carcinoma (UCa). The trial population was divided into two cohorts: Cohort A: participants with locally advanced unresectable or metastatic/recurrent UCa, who had confirmed disease progression during or following treatment with anti-programmed death receptor-1/programmed death receptor ligand-1 (anti-PD-1/PD-L1) therapy; Cohort B: participants with locally advanced unresectable or metastatic/recurrent UCa, who were treatment naïve and ineligible for cisplatin-based chemotherapy. A safety run-in was performed using a modified rolling six design, enrolling up to 6 participants (safety analysis participants) from Cohort A.
Conditions
- Urothelial Carcinoma
Interventions
INO-5401Biological
INO-5401: A mixture of 3 synthetic plasmids that target Wilms' tumor gene-1 (WT1) antigen, prostate-specific membrane antigen (PSMA) and human telomerase reverse transcriptase (hTERT) antigen. IM injection
INO-9012Biological
INO-9012: A synthetic plasmid that expresses human interleukin-12 (IL-12). IM injection.
AtezolizumabDrug
IV-Infusion.
CELLECTRA® 2000Device
IM injection.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Adverse Events of Special Interest (AESIs) TreatmentTime frame: Up to approximately 71 months
- Number of Participants With Clinically Significant Changes in Hematological ParametersTime frame: Up to approximately 71 months
- Number of Participants With Clinically Significant Changes in Serum Chemistry ParametersTime frame: Up to approximately 71 months
- Number of Participants With Clinically Significant Changes in Urinalysis ParametersTime frame: At baseline, Weeks 3, 6, 9, then every 6 weeks thereafter, up to 71 months
- Antigen-Specific Immune ResponseTime frame: Up to approximately 71 months
- Objective Response Rate (ORR) as Assessed by Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 by Investigator Review in Cohort ATime frame: From date of treatment start until date of first PD or death (whichever occurred first), up to approximately 71 months
Locations
11 sites in 1 country. Site status is shown where the registry gives one.
Mayo Clinic Cancer Center
Phoenix, Arizona
H. Lee Moffitt Cancer Center & Research Institute, Inc.
Tampa, Florida
Johns Hopkins University School of Medicine
Baltimore, Maryland
Karmanos Cancer Institute
Detroit, Michigan
Washington University School of Medicine in St. Louis
St Louis, Missouri
New York University Langone Medical Center - Perlmutter Cancer Center
New York, New York
Columbia University, Herbert Irving Comprehensive Cancer Center
New York, New York
University of North Carolina School of Medicine
Chapel Hill, North Carolina
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania
Greenville Memorial Hospital
Greenville, South Carolina
Inova Melanoma and Skin Cancer Center
Fairfax, Virginia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.